Mohamed Ezzelarab

Mohamed Ezzelarab

Auto-generated profile, based on publicly available information

Mohamed Ezzelarab

Department of Surgery, Thomas E. Starzl Transplantation Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2012 in Cell Stem Cell
Verified
Journal Article
Closed access
BHBrian P. Hermann
Brian P. Hermann
MSMeena Sukhwani
Meena Sukhwani
FWFelicity Winkler
Felicity Winkler
JPJulia N. Pascarella
Julia N. Pascarella
KPKaren A. Peters
Karen A. Peters
KOKyle E. Orwig
Kyle E. Orwig

1 September 2001 in Annals of Surgery
Verified
Journal Article
Closed access
KAKareem Abu-Elmagd
Kareem Abu-Elmagd
JRJorge Reyes
Jorge Reyes
GBGeoffrey Bond
Geoffrey Bond
GMGeorge Mazariegos
George Mazariegos
TWTong Wu
Tong Wu
TSThomas E. Starzl
Thomas E. Starzl
To assess the long-term efficacy of intestinal transplantation under tacrolimus-based immunosuppression and the therapeutic benefit of newly developed adjunct immunosuppressants and management strategies. With the advent of tacrolimus in 1990, transplantation of the intestine began to emerge as therapy for intestinal failure. However, a high risk of rejection, with the consequent need for acute and chronic high-dose immunosuppression, has inhibited its widespread application. During an 11-year period, divided into two segments by a 1-year moratorium in 1994, 155 patients received 165 intestinal allografts under immunosuppression based on tacrolimus and prednisone: 65 intestine alone, 75 liver and intestine, and 25 multivisceral. For the transplantations since the moratorium (n = 99), an adjunct immunosuppressant (cyclophos-phamide or daclizumab) was used for 74 transplantations, adjunct donor bone marrow was given in 39, and the intestine of 11 allografts was irradiated with a single dose of 750 cGy. The actuarial survival rate for the total population was 75% at 1 year, 54% at 5 years, and 42% at 10 years. Recipients of liver plus intestine had the best long-term prognosis and the lowest risk of graft loss from rejection (P = .001). Since 1994, survival rates have improved. Techniques for early detection of Epstein-Barr and cytomegaloviral infections, bone marrow augmentation, the adjunct use of the interleukin-2 antagonist daclizumab, and most recently allograft irradiation may have contributed to the better results. The survival rates after intestinal transplantation have cumulatively improved during the past decade. With the management strategies currently under evaluation, intestinal transplant procedures have the potential to become the standard of care for patients with end-stage intestinal failure.

1 February 2012 in The Lancet
Verified
Journal Article
Closed access
BEBurcin Ekser
Burcin Ekser
MEMohamed Ezzelarab
Mohamed Ezzelarab
HHHidetaka Hara
Hidetaka Hara
DWDirk J van der Windt
Dirk J van der Windt
MWMartin Wijkstrom
Martin Wijkstrom
DCDavid Kc Cooper
David Kc Cooper

17 March 2017 in Xenotransplantation
Verified
Journal Article
Closed access
PDF file
HIHayato Iwase
Hayato Iwase
HHHidetaka Hara
Hidetaka Hara
MEMohamed Ezzelarab
Mohamed Ezzelarab
TLTao Li
Tao Li
ZZZhongqiang Zhang
Zhongqiang Zhang
DCDavid Cooper
David Cooper

29 June 2015 in Xenotransplantation
Verified
Journal Article
Closed access
PDF file
HIHayato Iwase
Hayato Iwase
HLHong Liu
Hong Liu
MWMartin Wijkstrom
Martin Wijkstrom
HZHuidong Zhou
Huidong Zhou
JSJagjit Singh
Jagjit Singh
DCDavid Cooper
David Cooper

15 April 2019 in Xenotransplantation
Verified
Journal Article
Closed access
PDF file
DCDavid Cooper
David Cooper
HHHidetaka Hara
Hidetaka Hara
HIHayato Iwase
Hayato Iwase
TYTakayuki Yamamoto
Takayuki Yamamoto
QLQi Li
Qi Li
DADavid Ayares
David Ayares